The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Rapamycin causes regression of astrocytomas in tuberous sclerosis complex
Abstract
Objective: Tuberous sclerosis complex (TSC) is a genetic disorder characterized by the formation of hamartomas in multiple organs. Five to 15% of affected individuals display subependymal giant cell astrocytomas, which can lead to substantial neurological and postoperative morbidity due to the production of hydrocephalus, mass effect, and their typical location adjacent to the foramen of Monro. We sought to see whether therapy with oral rapamycin could affect growth or induce regression in astrocytomas associated with TSC. Methods: Five subjects with clinically definite TSC and either subependymal giant cell astrocytomas (n = 4) or a pilocytic astrocytoma (n = 1) were treated with oral rapamycin at standard immunosuppressive doses (serum levels 5–15ng/ml) from 2.5 to 20 months. All lesions demonstrated growth on serial neuroimaging studies. Magnetic resonance imaging scans were performed before and at regular intervals following initiation of therapy. Results: All lesions exhibited regression and, in one case, necrosis. Interruption of therapy resulted in regrowth of subependymal giant cell astrocytomas in one patient. Resumption of therapy resulted in further regression. Treatment was well tolerated. Interpretation: Oral rapamycin therapy can induce regression of astrocytomas associated with TSC and may offer an alternative to operative therapy of these lesions. Ann Neurol 2006
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phosphorylation and Functional Inactivation of TSC2 by Erk
Ma, L., Chen, Z., Erdjument-Bromage, H., Tempst, P., & Pandolfi, P. P. (2005) · Cell · doi:10.1016/j.cell.2005.02.031 · Cited by 1,268
Galanis, E., Buckner, J. C., Maurer, M. J., Kreisberg, J. I., Ballman, K., Boni, J., Peralba, J. M., Jenkins, R. B., Dakhil, S. R., Morton, R. F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.622 · Cited by 694
mTOR-targeted therapy of cancer with rapamycin derivatives
Vignot, S., Faivre, S., Aguirre, D., & Raymond, E. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi113 · Cited by 617
An expanding role for mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2005) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2005.06.007 · Cited by 523
Rhebbing up mTOR: New Insights on TSC1 and TSC2, and the Pathogenesis of Tuberous Sclerosis
Kwiatkowski, D. J. (2003) · Cancer Biology & Therapy · doi:10.4161/cbt.2.5.446 · Cited by 387 · cited 1×
“When mTOR is constitutively activated through mutations in either hamartin or tuberin, this results in the hamartomatous lesions of tuberous sclerosis in the brain, kidney, heart, lung, and other organs of the body (Fig 1).(8,9) Recent studies have also shown that to function under homeostatic conditions, the mTOR pat…”
BackgroundBoulay, A., Rudloff, J., Ye, J., Zumstein-Mecker, S., O'Reilly, T., Evans, D. B., Chen, S., & Lane, H. A. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2402 · Cited by 335
Dasgupta, B., Yi, Y., Chen, D. Y., Weber, J. D., & Gutmann, D. H. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4058 · Cited by 308
Hepatocellular Carcinoma: Molecular Pathways and New Therapeutic Targets
Roberts, L. R., & Gores, G. J. (2005) · Seminars in Liver Disease · doi:10.1055/s-2005-871200 · Cited by 289
Rapamycin: an anti-cancer immunosuppressant?
Law, B. K. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.09.009 · Cited by 252
Goudar, R. K., Shi, Q., Hjelmeland, M. D., Keir, S. T., McLendon, R. E., Wikstrand, C. J., Reese, E. D., Conrad, C. A., Traxler, P., Lane, H. A., et al. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.101.4.1 · Cited by 243
mTOR: a protein kinase switching between life and death
ASNAGHI, L., BRUNO, P., PRIULLA, M., & NICOLIN, A. (2004) · Pharmacological Research · doi:10.1016/j.phrs.2004.03.007 · Cited by 230
Wu, L., Birle, D. C., & Tannock, I. F. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3137 · Cited by 164
Effects of Rapamycin in the Eker Rat Model of Tuberous Sclerosis Complex
Kenerson, H., Dundon, T. A., & Yeung, R. S. (2005) · Pediatric Research · doi:10.1203/01.pdr.0000147727.78571.07 · Cited by 162
Mechanisms of resistance to rapamycins
Huang, S., & Houghton, P. J. (2001) · Drug Resistance Updates · doi:10.1054/drup.2002.0227 · Cited by 143
Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF
Guba, M. O., Yezhelyev, M., Eichhorn, M., Schmid, G., Ischenko, I., Papyan, A., Graeb, C., Seeliger, H., Geissler, E. K., Jauch, K., et al. (2005) · Blood · doi:10.1182/blood-2004-09-3540 · Cited by 127
Jiang, W. G., Sampson, J. R., Martin, T. A., Lee‐Jones, L., Watkins, G., Douglas-Jones, A. G., Mokbel, K., & Mansel, R. E. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.03.023 · Cited by 100
Early Diagnosis of Subependymal Giant Cell Astrocytoma in Patients With Tuberous Sclerosis
Torres, O., Roach, E. S., Delgado, M. R., Sparagana, S. P., Sheffield, E. G., Swift, D. M., & Bruce, D. A. (1998) · Journal of Child Neurology · doi:10.1177/088307389801300405 · Cited by 99
Chapman, T. M., & Perry, C. M. (2004) · Drugs · doi:10.2165/00003495-200464080-00005 · Cited by 78
The rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation.
Asano, T., Yao, Y.-X., Zhu, J.-J., Li, D.-H., Abbruzzese, J., & Reddy, S. A. (2005) · Biochemical and Biophysical Research Communications - BBRC · doi:10.1016/j.bbrc.2005.03.166 · Cited by 74
Nobukuni, T., & Thomas, G. (2004) · Novartis Foundation symposium · doi:10.1002/0470869976.ch9 · Cited by 57
Self-citationEl-Hashemite, N., Zhang, H., Walker, V., Hoffmeister, K. M., & Kwiatkowski, D. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3609 · Cited by 54
Mechanisms of action of rapamycin in gliomas
Heimberger, A. B., Wang, E., McGary, E. C., Hess, K. R., Henry, V. K., Shono, T., Cohen, Z. R., Gumin, J., Sawaya, R. A., Conrad, C. A., et al. (2005) · Neuro-Oncology · doi:10.1215/s1152851704000420 · Cited by 36
Inhibition of mTOR suppresses experimental liver tumours.
Rizell, M., & Lindnér, P. (2005) · PubMed · Cited by 25
Cited by
Defining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833
The Tuberous Sclerosis Complex
Crino, P. B., Nathanson, K. L., & Henske, E. P. (2006) · New England Journal of Medicine · doi:10.1056/nejmra055323 · Cited by 1,793
Northrup, H., Krueger, D. A., Northrup, H., Krueger, D. A., Roberds, S., Smith, K., Sampson, J., Korf, B., Kwiatkowski, D. J., Mowat, D., et al. (2013) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2013.08.001 · Cited by 1,502
Self-citationCarracedo, A., Ma, L., Teruya-Feldstein, J., Rojo, F., Salmena, L., Alimonti, A., Egia, A., Sasaki, A. T., Thomas, G., Kozma, S. C., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34739 · Cited by 1,381
Self-citationmTOR and cancer: insights into a complex relationship
Sabatini, D. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1974 · Cited by 1,322
Metadata
- Authors
- Franz, D. N., Leonard, J., Tudor, C., Chuck, G., Care, M., Sethuraman, G., Dinopoulos, A., Thomas, G., & Crone, K. R.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2006-02-17
- Volume
- 59
- Issue
- 3
- Pages
- 490-498
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2032555040
- Cited by
- 614
- References
- 23
- FWCI
- 26.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.